Epidemiology of idiopathic pulmonary fibrosis

Brett Ley
Harold R Collard
Department of Medicine, Division of Pulmonary and Critical Care Medicine, University of California San Francisco, San Francisco, California, USA

Abstract: Idiopathic pulmonary fibrosis is a chronic fibrotic lung disease of unknown cause that occurs in adults and has a poor prognosis. Its epidemiology has been difficult to study because of its rarity and evolution in diagnostic and coding practices. Though uncommon, it is likely underappreciated both in terms of its occurrence (ie, incidence, prevalence) and public health impact (ie, health care costs and resource utilization). Incidence and mortality appear to be on the rise, and prevalence is expected to increase with the aging population. Potential risk factors include occupational and environmental exposures, tobacco smoking, gastroesophageal reflux, and genetic factors. An accurate understanding of its epidemiology is important, especially as novel therapies are emerging.

Keywords: idiopathic pulmonary fibrosis, epidemiology, incidence, prevalence, mortality, risk factors

Introduction

Idiopathic pulmonary fibrosis (IPF) is a specific form of chronic progressive fibrotic lung disease of unknown cause.1,2 It occurs primarily in middle-aged to older adults and is characterized by the underlying histopathological pattern of usual interstitial pneumonia. Its pathobiology is complex and is hypothesized to be driven by the loss of alveolar epithelial cell integrity due to aging, genetic and epigenetic factors, and reactivation of developmental signaling pathways.3

Progressive fibrosis with loss of normal lung tissue leads to restricted ventilation, impaired gas exchange, respiratory symptoms and exercise limitation, poor quality of life, and ultimately death. Unfortunately, there are no definitive therapies for IPF, with only one drug shown to potentially slow the progression of disease in clinical trials,4 and surgical therapy with lung transplantation available to only a small minority of patients.

We are living in a time of great opportunity and promise in the field of IPF. With central advances in our understanding of disease mechanism, the development of novel agents by academia and industry, and the formation of multicenter networks experienced in the conduct of large clinical trials, there is good reason to believe that we are on the verge of developing multiple effective therapies. As the management options for IPF patients improve, an accurate understanding of the epidemiology of IPF will be important so that health care systems and policy-makers are adequately prepared to facilitate care.
Historical challenges in studying the epidemiology of IPF

The epidemiology of IPF remains poorly described for many reasons, but changes in definitions of IPF and complex diagnostic algorithms have proven major challenges. Since the early pathological descriptions of interstitial pneumonia by Hamman and Rich in 1944,5 multiple conditions that we now consider separate disease entities (eg, nonspecific interstitial pneumonia and desquamative interstitial pneumonia) were lumped in with IPF or one of its other names (eg, cryptogenic fibrosing alveolitis). In 1998, Katzenstein and Myers proposed that the term IPF be reserved for those patients with a histopathological pattern of usual interstitial pneumonia and no identifiable cause for their interstitial lung disease (ILD).6 This concept was formalized into diagnostic criteria in the first international consensus statement on IPF in 20001 and revised in 2011 (Table 1).2 Additionally, these statements have emphasized the importance of a multidisciplinary approach to accurate diagnosis through consensus that includes discussion among pulmonologists, radiologists, and pathologists with expertise in ILDs. This evolution is reflected in the confusing nomenclature of International Classification of Disease (ICD) codes that have historically encompassed the disease (Table 1).

Prevalence and incidence

The published literature suggests that IPF is the first or second most commonly encountered ILD in pulmonology practices (range 17%–86%).7–11 Its overall incidence and prevalence, however, are unclear (Table 2). Geographically, most studies come from the United States12–14 and Europe (United Kingdom,15,16 Czech Republic,17 Norway,18 Finland,19 Greece,8 and Turkey9), with only two studies reported from Asia (Japan11 and Taiwan20). Most of these studies included

---

**Table 1** Diagnostic criteria for idiopathic pulmonary fibrosis and International Classification of Disease (ICD) code nomenclature

<table>
<thead>
<tr>
<th>Statement/ICD code</th>
<th>Definition/criteria</th>
</tr>
</thead>
<tbody>
<tr>
<td>ATS/ERS 20001</td>
<td>Surgical lung biopsy showing UIP and</td>
</tr>
<tr>
<td></td>
<td>1. Exclusion of secondary causes (ie, drugs, environmental exposures, collagen vascular diseases)</td>
</tr>
<tr>
<td></td>
<td>2. Abnormal PFTs showing restriction and/or impaired gas exchange</td>
</tr>
<tr>
<td></td>
<td>3. Consistent abnormalities on chest X-ray or HRCT</td>
</tr>
<tr>
<td></td>
<td>or</td>
</tr>
<tr>
<td></td>
<td><strong>Without a surgical lung biopsy must meet</strong></td>
</tr>
<tr>
<td></td>
<td>All major criteria</td>
</tr>
<tr>
<td></td>
<td>Exclusion of secondary causes, abnormal PFTs, bibasilar reticular abnormalities with minimal ground glass opacities on HRCT, TBB, or BAL without features of an alternative diagnosis</td>
</tr>
<tr>
<td></td>
<td>plus</td>
</tr>
<tr>
<td></td>
<td>3 of 4 minor criteria</td>
</tr>
<tr>
<td></td>
<td>Age &gt;50 years, insidious onset of otherwise unexplained dyspnea on exertion, duration of illness of at least 3 months, bibasilar inspiratory crackles</td>
</tr>
<tr>
<td></td>
<td>1. Exclusion of secondary causes</td>
</tr>
<tr>
<td></td>
<td>2. UIP pattern on HRCT in patients without a surgical lung biopsy or specific combinations of HRCT and surgical lung biopsy patterns:</td>
</tr>
<tr>
<td>HRCT pattern</td>
<td>Surgical lung biopsy pattern</td>
</tr>
<tr>
<td></td>
<td>UIP</td>
</tr>
<tr>
<td>UIP</td>
<td>IPF</td>
</tr>
<tr>
<td>Possible UIP</td>
<td>IPF</td>
</tr>
<tr>
<td>Inconsistent with UIP</td>
<td>MDD</td>
</tr>
</tbody>
</table>

**ICD-8**
- 517 Other chronic interstitial pneumonia
- 515 Postinflammatory pulmonary fibrosis
- 516.3 Idiopathic fibrosing alveolitis
- **ICD-10**
- J84.1 Idiopathic pulmonary fibrosis

*Abbreviations: ALAT, Latin American Thoracic Association; ATS, American Thoracic Society; BAL, bronchoalveolar lavage; ERS, European Respiratory Society; HRCT, high-resolution computed tomography; ICD, International Classification of Disease; IPF, idiopathic pulmonary fibrosis; JRS, Japanese Respiratory Society; MDD, further multidisciplinary discussion required; PFTs, pulmonary function tests; TBB, transbronchial biopsy; UIP, usual interstitial pneumonia.*
patients diagnosed prior to the redefinition of IPF in 2000, and strategies for case ascertainment within the source population varied from exclusive reliance on diagnostic codes (low diagnostic specificity), to surveys of clinicians at subspecialty clinics (low diagnostic sensitivity), to a combination of searching administrative data and focused review of medical records (potentially improving diagnostic sensitivity and specificity). With these issues in mind, the published prevalence of IPF has ranged from 0.7 per 100,000 person years to 63.0 per 100,000 in the United States, and the published incidence has ranged from 0.6 per 100,000 person years to 17.4 per 100,000 person years (Table 2). It is unclear how much of this variation among studies is due to geographic or demographic differences in the risk of IPF. Below is a brief overview of selected studies.

### United States

**Coultas et al.**

This study used multiple sources including clinician surveys, pathology reports, discharge diagnoses, death certificates, and autopsies from Bernalillo County, New Mexico between 1988 and 1990. Using the diagnostic code for idiopathic fibrosing alveolitis (ICD-9 code 516.3), an overall prevalence of IPF of 13.2 per 100,000 for women and 20.2 per 100,000 for men (incidence 7.4 per 100,000 person years and 10.7 per 100,000 person years for men and women, respectively) were reported.

**Raghu et al.**

This study queried a large private health insurance claims database that included patients from 20 states in the United States for calendar year 2000. Cases were again identified by ICD-9 code 516.3 and exclusion of associated conditions (broad definition), with a subgroup analysis requiring additional claims for lung biopsy or chest computed tomography scan, indicating a relevant diagnostic evaluation had taken place (narrow definition). The prevalence was 42.7 per 100,000 (14 per 100,000 for the narrow definition) and the incidence was 16.3 per 100,000 person years (6.8 per 100,000 person years for the narrow definition). This translated to an estimated

### Table 2 Prevalence and incidence of idiopathic pulmonary fibrosis by geography

<table>
<thead>
<tr>
<th>Geography</th>
<th>Study year(s)</th>
<th>Prevalence (per 100,000)</th>
<th>Incidence (per 100,000/y)</th>
<th>Case ascertainment</th>
</tr>
</thead>
<tbody>
<tr>
<td>United States</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>(Bernalillo County)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Twenty states</td>
<td>2000</td>
<td>14.0–42.7†</td>
<td>6.8–16.3†</td>
<td>Private insurance claims database ICD-9 516.3</td>
</tr>
<tr>
<td>Minnesota</td>
<td>1997–2005</td>
<td>27.9–63.0§</td>
<td>8.8–17.4§</td>
<td>Population-based medical record linkage system (2000 ATS/ERS criteria)</td>
</tr>
<tr>
<td>(Olmsted County)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Europe</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Czech Republic</td>
<td>1981–1990</td>
<td>6.5–12.1§</td>
<td>0.74–1.28§</td>
<td>Clinical registry</td>
</tr>
<tr>
<td>Norway</td>
<td>1984–1998</td>
<td>23.4</td>
<td>4.3</td>
<td>Hospital district records</td>
</tr>
<tr>
<td>Finland</td>
<td>1997–1998</td>
<td>16–18</td>
<td>–</td>
<td>Pulmonary clinics and hospital database ICD-10 J84.1, subset reviewed</td>
</tr>
<tr>
<td>Greece</td>
<td>2004</td>
<td>3.4</td>
<td>0.9</td>
<td>Survey of pulmonary practices</td>
</tr>
<tr>
<td>Turkey</td>
<td>2007–2009</td>
<td>–</td>
<td>4.9§</td>
<td>Survey of pulmonary practices</td>
</tr>
<tr>
<td>Asia</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Taiwan</td>
<td>1997–2007</td>
<td>0.7–6.4§</td>
<td>0.6–1.4§</td>
<td>Medical benefits records and subset medical record review for IIIPs</td>
</tr>
<tr>
<td>Japan</td>
<td>2005</td>
<td>2.9§</td>
<td>–</td>
<td>National health insurance database ICD-9 516.3</td>
</tr>
</tbody>
</table>

**Notes:** †Range reported for men and women, respectively; ‡Range reported for narrow and broad case definitions; §Range reported for rates over the study period; †Incident cases for ILD reported as 25.8 per 100,000/y, where 19.9% were IPF; ‡Range reported for the broad definition over the study period; †Prevalence reported for all IIIPs as 3.4 per 100,000, of which 85.7% were reported to be IPF.

**Abbreviations:** ATS, American Thoracic Society; ERS, European Respiratory Society; ICD-8, -9, -10, International Classification of Disease-eighth, ninth, or tenth revisions; IIIP, idiopathic interstitial pneumonia; y, year; ILD, interstitial lung disease; IPF, idiopathic pulmonary fibrosis.
89,000 patients living with IPF in the United States in the year 2000 with 34,000 new cases diagnosed per year.

Both the Coultas and Raghu studies also provided estimates using the more generic diagnostic code for post-inflammatory pulmonary fibrosis (ICD-9 code 515). Figure 1 demonstrates the impact of this more inclusive (ie, more sensitive, less specific) definition. The wide variation in the prevalence of ICD-9 code 515 between studies may reflect methodological and/or coding practice differences.

Fernández-Pérez et al

This was a small population-based study in Olmsted County, Minnesota from 1997–2005 (source population of approximately 128,000 primarily White, residents) utilizing a county-wide medical record linkage system. Cases were first identified by administrative codes and then verified via audit of patient-level data in accordance with the revised IPF definition. Investigators identified a total of 47 cases meeting the primary case definition corresponding to an age and sex-adjusted prevalence of 63 per 100,000 and an incidence of 17.4 per 100,000 person years. Incidence rates decreased over the study period.

Europe

Gribbin et al

This study interrogated a longitudinal primary care database representing 25% of practices within the United Kingdom for the diagnostic terms cryptogenic or idiopathic fibrosing alveolitis between 1991 and 2003. An audit of IPF cases in this database found that 19 of 20 were accurate, supporting diagnostic validity, although the audit occurred prior to the revised criteria. The overall annual incidence of IPF was 4.6 per 100,000 person years. Incidence increased over the study period, about 11% per year. The investigators reported a follow up study with similar methods, albeit with slightly more inclusive search terms, for patients identified from 2000–2009, and found that incidence continued to increase. The increasing incidence was not accounted for by the effect of an aging population.

von Plessen et al

This study searched multiple ICD-8 and ICD-9 codes in one hospital district in Norway between 1984 and 1998. Medical records were reviewed and cases excluded if alternative diagnoses appeared more likely. Prevalence was found to be 23.4 per 100,000, and the incidence was 4.3 per 100,000 person years.

Hodgson et al

These researchers performed a nation-wide survey of pulmonary practices in Finland and searched hospital databases for ICD-10 code J84.1 in 1997–1998. A case audit was performed at a subset of centers finding that 49%–77% met revised diagnostic criteria. Prevalence was found to be 16 to 18 per 100,000.

Karakatsani et al

In Greece, this study surveyed pulmonary specialty clinics in 2004 for cases of ILD (an approach likely to underestimate disease occurrence compared to population-based approaches), with clinicians instructed to apply consensus criteria. The reported prevalence (3.4 per 100,000) and incidence (0.9 per 100,000 person years) of IPF were much lower than other reports from the United States and Europe.

Musellim et al

Similar methodology to Karakatsani et al was used for another study in Turkey, performed from 2007 to 2009. The reported incidence of IPF was 4.9 per 100,000 person years.

Asia

Ohno et al

These investigators searched medical benefit certificates for all idiopathic interstitial pneumonias in Japan in 2005, with clinical data available for review in 35% of cases. The incidence of idiopathic interstitial pneumonia was 3.4 per 100,000 person years, and 85.7% were considered due to IPF.

Figure 1 The prevalence of idiopathic pulmonary fibrosis varies widely depending on case definitions in epidemiologic studies.

Notes: There is marked variation with the use of ICD-9 code 515 (postinflammatory pulmonary fibrosis) and/or ICD-9 code 516.3 (idiopathic fibrosing alveolitis) to identify cases, with or without added levels of stringency. The Raghu et al broad definition required the presence of ICD-9 code 516.3 or 515 and exclusion of other diagnoses that cause interstitial lung disease. The Raghu et al narrow definition required the broad definition plus additional procedure codes for lung biopsy and radiology studies. The Coultas et al cases were drawn from multiple administrative and clinical sources. Estimates are shown for men in the 65–74 year age group from Raghu et al and Coultas et al.
This study searched the Taiwanese national health insurance system for ICD-9 code 516.3 from 1997 to 2007 and applied narrow and broad case definitions similar to the Raghu et al study. The prevalence was 0.7 to 6.4 per 100,000, and the incidence was 0.6 to 1.4 per 100,000 person years.

In both the Ohno and Lai studies, disease severity was high, suggesting that the lower estimates were due to low case ascertainment rates, with only more severe cases recognized.

Many of the above studies evaluated rates of IPF by age and sex. Prevalence and incidence of IPF are clearly higher in older age groups (Figure 2), a finding consistent with the role of aging in the pathogenesis of IPF. IPF also appears to be more common in men compared to women, however, some postulate this may be due to sex differences in historical smoking patterns rather than an inherent sex-related risk for IPF.

### Risk factors

Several potential risk factors for the development of IPF have been identified. These include environmental and occupational exposures, tobacco smoking, comorbidities (in particular gastroesophageal reflux disease [GERD]), and genetic polymorphisms (Table 3). The identification of risk factors for IPF is critically important as it may inform prevention strategies, early diagnosis, and novel therapies.

### Inhaled exposures

Multiple lines of evidence lend support to the plausibility of inhaled exposures contributing to at least some cases of IPF. First, basic science and animal studies support the concept of repetitive alveolar epithelial cell stress due to an array of potential inciting agents in the pathogenesis of IPF. Second, epidemiologic studies have observed geographic variation within countries in the occurrence of IPF, particularly in highly industrialized regions. There is also a higher occurrence in men compared to women who, at least historically, were more likely to smoke and to work in dusty occupations. Third, well-defined occupational lung diseases such as asbestosis and silicosis clearly cause fibrotic lung disease, leaving open the possibility that less well-characterized exposures may do so as well. Fourth, autopsy studies have revealed higher levels of inorganic particles, such as silicon and aluminum, in the hilar lymph nodes of patients with IPF compared to controls.

With these observations in mind, several studies have demonstrated an association of certain environmental and occupational exposures with IPF. As with incidence and prevalence estimation studies, diagnostic misclassification (particularly for studies performed prior to the IPF statements) introduces the potential for faulty associations.

In 2006, Taskar and Coultas reviewed six case-control studies, performed in three countries (United States, United Kingdom, Japan), that compared a total of 711 patients with IPF to 1,491 controls. Exposures with...
significant associations in at least one study included agriculture/farming, hairdressing, birds, animal/vegetable dust, livestock, wood dust, textile dust, mold, metal dust, stone/sand/silica, wood fires, and tobacco smoking.\textsuperscript{30–35} Meta-analysis of exposures with at least two studies demonstrated a significant association for agriculture/farming (odds ratio [OR] 1.65, 95% confidence interval [CI] 1.20–2.26, and population attributable risk [PAR] 20.8%), livestock (OR 2.17, 95% CI 1.28–3.68, PAR 4.1%), wood dust (OR 1.94, 95% CI 1.34–2.81, PAR 5.0%), metal dust (OR 2.44, 95% CI 1.74–3.40, PAR 3.4%), stone/sand/silica (OR 1.97, 95% CI 1.09–3.55, PAR 3.5%), and smoking (OR 1.58, 95% CI 1.27–1.97, PAR 49.1%).\textsuperscript{34} A dose-response has been suggested for metal dust exposure\textsuperscript{34} and moderate smoking\textsuperscript{48,49} Interestingly, less than half of IPF patients with abnormal gastroesophageal reflux report classic symptoms (eg, heartburn, regurgitation) making it difficult to identify these patients clinically.\textsuperscript{44–47}

### Gastroesophageal reflux

There is strong evidence linking GERD to the presence and progression of IPF, but causation is unproven. GERD is hypothesized to lead to chronic microaspiration of gastric contents, both acid and nonacid, causing repetitive lung injury and resulting pulmonary fibrosis in susceptible individuals.\textsuperscript{43} This concept is supported by animal studies,\textsuperscript{45} an elevated prevalence of GERD in patients with IPF (67%–94%),\textsuperscript{44–47} and an association in retrospective studies of GERD treatment with improved survival and reduced disease progression in IPF.\textsuperscript{48,49} Interestingly, less than half of IPF patients with abnormal gastroesophageal reflux report classic symptoms (eg, heartburn, regurgitation) making it difficult to identify these patients clinically.\textsuperscript{44–47}

### Genetics

Familial IPF is defined as IPF occurring in two or more first-degree relatives within the same biologic family.\textsuperscript{2–50} Familial IPF is thought to represent <5% of cases of IPF and is generally indistinguishable from sporadic cases.\textsuperscript{51} Genes associated with familial IPF include telomerase-related genes (TERT and TERC),\textsuperscript{52,53} surfactant proteins C (SPC)\textsuperscript{54–56} and A2 (SP2)\textsuperscript{57}, and ELMOD2.\textsuperscript{58} Mutations in TERT or TERC have been identified in about 18% of familial IPF and less
commonly in sporadic cases. These mutations result in shortened telomere lengths in both affected individuals and asymptomatic carriers, and shortened telomere lengths have also been demonstrated in noncarrier family members, suggesting an epigenetic inheritance of short telomeres. Also, 25% of sporadic and 37% of familial cases without mutations in have short telomeres, suggesting other mechanisms for telomere shortening that are not due to mutations in TERT/TERC for 129 patients with a known clinical diagnosis of ILD. In their population-based study, Fernández-Pérez et al found that 79% of IPF patients in Olmsted county, Minnesota required one or more hospitalizations for acute respiratory worsening at a rate of 0.13 hospitalizations per patient year. In the UK, Navarattanam et al explored hospitalization for IPF from 1998 to 2010. The admission rate for ICD-10 code J84.1 averaged 14.95 per 100,000 person years and increased by approximately 5% per year. Admission rates were greater in older patients and in men. The average length of stay decreased from 7.2 days to 5.1 days, but the estimated financial burden of hospitalization increased from £12 million to £16.2 million per year. Collard et al assessed the overall burden of illness in IPF including comorbidities, health care resource utilization, and health care costs by searching two United States insurance claims databases between 2001 and 2008. Cases of IPF required both age >55 years old and at least two claims of ICD-9 code 516.3 or one claim each with ICD-9 code 516.3 and 515. An age and sex-matched population lacking these codes was used for control comparisons. Pulmonary hypertension, emphysema, pulmonary embolism, chronic bronchitis, pulmonary infection, and lung cancer were all more common in IPF patients than controls. Risk was also increased for many common chronic diseases, such as coronary artery disease, diabetes, congestive heart failure, and GERD. The all-cause hospitalization rate (0.5 per person year), the days in hospital (3.1 days per person year), and the outpatient visit rate (28 visits per person year) were two-fold higher than for controls, and the inpatient death rate was more than three-fold higher than for controls. The average annual direct costs were about two-fold higher for IPF patients compared to controls, amounting to an incremental annual cost of $12,124. Based on a prevalence of 89,000 patients with IPF in the United States, it was estimated that the aggregate incremental cost due to IPF was over $1 billion per year.

Mortality

IPF-related mortality refers to the proportion of people dying per year in the general population in whom IPF is considered the underlying cause of death or an associated cause of death. IPF-related mortality data are typically obtained from national registries compiled from information on death certificates. These studies are generally limited by disease under-recognition (patients with IPF are not captured) and diagnostic misclassification (patients with IPF are mislabeled). Coulta and Hughes evaluated death certificates for 129 patients with a known clinical diagnosis of ILD. Looking at potential IPF cases (ICD-9 code 515 and 516.3 combined), 36 of 71 patients with the diagnosis prior to death had it listed anywhere on the death certificate (diagnostic sensitivity 51%). There was a high degree of reclassification between ICD-9 codes 515 and 516.3 comparing predeath and death certificate diagnoses. Johnston et al reported similar findings. These data taken together suggest that mortality
data from national death registries underestimate IPF-related mortality.

Three studies examined mortality from IPF in the 1970s to early 1990s in the United Kingdom, United States, Germany, Australia, New Zealand, and Canada. Major findings were that IPF-related mortality 1) increased in most countries over this time period, 2) was higher in older patients and in men, and 3) had regional variations within countries. These studies also highlighted a marked difference in rates of ICD-9 code 516.3 versus 515 among the countries, reflecting differences in country-specific coding practices.

Olson et al investigated mortality rates in IPF by searching the United States death registry from 1992 to 2003. IPF was identified as records containing ICD-9 code 516.3 or 515 (from 1992–1998) and ICD-10 code J84.1 (from 1998–2003) excluding those containing codes for other ILDs. The average age and sex-adjusted mortality was 5.08 per 100,000 person years, which is similar to contemporary incidence estimates in the United States (6.8 per 100,000 patients years to 8.8 per 100,000 patient years). Mortality was higher than previously reported and increased by 34% over the study period. Although mortality rates were higher for men compared to women, they increased more rapidly in women, potentially due to changes in smoking patterns. Mortality rates were higher in older age groups and in Whites compared to Blacks and Hispanics. IPF was the most common underlying cause of death in patients with IPF (60%), with other common causes including ischemic heart disease, lung cancer, pneumonia, cerebrovascular disease, heart failure, and pulmonary embolism. Interestingly, the proportion of patients dying from IPF, rather than with IPF, was greater in this study than in previous reports. The authors speculate this may be due to effective therapies for competing causes of death, such as cardiovascular disease, outpacing those for IPF.

In a follow up study using similar methods during the years 1989 to 2007, these investigators further explored racial and ethnic differences in IPF mortality. Of all IPF-related deaths, 87.2% occurred in Whites, 5.1% in Blacks, 5.4% in Hispanics, and 2.2% in other racial/ethnic groups. Compared to Whites, Blacks were less likely (OR 0.47) and Hispanics (OR 1.45) and other groups (1.29) more likely to have IPF encoded on their death certificates after adjusting for age and sex.

Navaratnam et al searched national mortality statistics in the United Kingdom for underlying cause of death from 1968 to 2008 using ICD-8, ICD-9, and ICD-10 codes spanning this period. Mortality, standardized to the 2008 population, increased from 0.92 per 100,000 person years in 1968–1972 to 5.1 per 100,000 person years in 2005–2008; an annual increase of 5% after controlling for age and sex. Again, mortality rates were higher in men and older age groups.

Whether the increasing mortality from IPF is due to a true increase in mortality or is a consequence of recognition or reporting bias is uncertain. In public health terms, IPF-related mortality is similar in magnitude to that of many malignancies (eg, non-Hodgkin’s lymphoma, renal cancer, esophageal cancer).

Conclusion

Idiopathic pulmonary fibrosis is an uncommon disease, but its incidence and prevalence appear to be increasing, and may be higher than reported in the literature because of reporting and recognition bias. There is still a lot we have to learn about the epidemiology of the disease; at present, there are entire continents without any available data on the occurrence of IPF. The risk of developing IPF is likely due to both host and environmental factors, and their elucidation may lead to improved prevention and treatment strategies. The personal and financial costs of IPF are substantial, and therapies to reduce the burden of illness from IPF are sorely needed.

Disclosure

HRC has served as consultant for Biogen, FibroGen, Genoa, Gilead, InterMune, MedImmune, Promedior, and Pfizer; has received grants from Boehringer-Ingeheim, Genentech, and the National Institutes of Health National Heart, Lung, and Blood Institute; has received royalties from UpToDate; and has received payment for development of educational presentations from MedScape. BL reports no conflicts of interest in this work.

References


